Table 1.
Subject demographics.
| RACE/ETHNICITY | |
| Black non-hispanic | 7 (46.7%) |
| Hispanic | 7 (46.7%) |
| Other | 1 (6.7%) |
| Age at 3rd trimester (years) | 25.6 (19.5–42.66) |
| Weight at 3rd trimester visit (kg) | 76.6 (48–101.5) |
| Gestational age at 3rd trimester visit (weeks) | 33.7 (30.3–36.7) |
| Weeks after delivery at postpartum PK visit | 5.9 (3–8.4) |
| OTHER ANTIRETROVIRALS | |
| Raltegravir | 9 (60%) |
| Darunavir, ritonavir | 6 (40%) |
| Truvada (emtricitabine, tenofovir) | 4 (27%) |
| Kaletra (lopinavir, ritonavir) | 3 (20%) |
| Combivir (lamivudine, zidovudine) | 2 (13%) |
| Maraviroc | 2 (13%) |
| Duration of etravirine therapy at 3rd trimester visit (weeks) | 12.7 (4.6–91.6) |
| HIV-1 RNA AT DELIVERY | |
| <50 copies/mL | 9 (75%) |
| <400 copies/mL | 10 (83%) |
| CD4 at delivery | 420 (107–610) |
| Infant gestational age at birth (weeks) | 38.6 (36–41.7) |
| Infant weight at birth (g) | 3205 (2620–3800) |
| Infant length at birth (cm) | 50 (45–52) |
| INFECTION STATUS | |
| Negative based on best available data | 13 (100%) |
N = 15 for pregnant HIV-infected women and n = 13 for infants. Data are represented as n (%) or median (range).